

## **Suven Life Sciences Ltd to present key Scientific Data at the Alzheimer's Association International Conference 2021 (AAIC), Denver, USA**

HYDERABAD, INDIA (July 26, 2021) – Suven Life Sciences presenting three e-posters from Suven's portfolio of investigational Neuroscience New Chemical Entities (NCEs) at Alzheimer's Association International Conference (AAIC) being held during 26-30 July, 2021 in Denver, USA Virtually. AAIC is the largest and most influential International conference dedicated to advancing dementia science. Suven has excellent portfolio of new molecules through different mechanism of action using 5-HT<sub>6</sub>, 5-HT<sub>4</sub>, H<sub>3</sub> receptors and M<sub>1</sub>PAM for the treatment of cognitive impairment and neuro-psychiatric symptoms in Alzheimer's disease and other dementia.

AAIC accepted Presentations:

51571- Masupirdine (SUVN-502): A promising clinical candidate for the management of agitation in Alzheimer's dementia.

51644- Usmarapride (SUVN-D4010): A serotonin-4 receptor partial agonist for the treatment of cognitive disorders.

51652- SUVN-I6107: Efficacy and safety assessments of a true muscarinic M<sub>1</sub> positive allosteric modulator for the treatment of dementia.

Masupirdine (SUVN-502) completed clinical Phase-2 study in USA and ready for a potential Phase-3 study. Usmarapride (SUVN-D4010) completed clinical Phase-1 studies and ready for Phase-2 study. SUVN-I6107 currently undergoing GLP tox studies and will be ready for clinical Phase-1 studies by end of 2021.

### ***Disclaimer and Risk Statement:***

***Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.***

## **Suven Life Sciences Limited**